Thrombosis Research
Volume 121, Issue 2 , Pages 175-181, 2007

Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome

  • Mika Skeppholm

      Affiliations

    • Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiology, SE-182 88 Stockholm, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 8 6556847.
  • ,
  • N. Håkan Wallén

      Affiliations

    • Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiology, SE-182 88 Stockholm, Sweden
  • ,
  • Karin Malmqvist

      Affiliations

    • Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiology, SE-182 88 Stockholm, Sweden
  • ,
  • Anders Kallner

      Affiliations

    • Department of Clinical Chemistry Karolinska University Hospital, Solna, Sweden
  • ,
  • Jovan P. Antovic

      Affiliations

    • Department of Mol Med and Surgery, Karolinska Institutet, Div of Clin Chem and Blood Coagulation Research, Karolinska University Hospital, Solna, Sweden

Received 8 September 2006; received in revised form 26 March 2007; accepted 27 March 2007.

Abstract 

TAFI was measured as relative activity concentration (Pefakit) and antigen concentration (Haemochrom and Asserachrom) both acutely and during convalescence in patients suffering from acute coronary syndrome, and in a group of healthy controls. There was a rather weak but significant correlation between the activity and antigen concentrations. The results obtained by the Haemochrom method, assumed to measure the concentrations of all forms of TAFI, were lower than those by the Asserachrom method although the latter is assumed to only measure the pro-TAFI concentration. Both immunoassays gave lower results than the functional method (Pefakit). The patients in the convalescence phase showed a higher activity concentration than the healthy controls. The Asserachrom showed a higher concentration in the acute and convalescence phases of the patients compared to the controls, whereas the Haemochrom did not show any such difference. This could be related to different species of the TAFI molecule and thus different reactivity to the antibodies. Therefore the optimal choice of assay for determination of TAFI in different clinical studies is of importance. The Pefakit and Asserachrom seem to be appropriate candidates.

Keywords: ELISA, Polymorphism, Kinetic assay, Acute coronary syndrome (ACS), TAFI, Chromogenic substrates

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Financial support for this investigation was obtained from the Heart and Lung Foundation Sweden, Stiftelsen Serafimerlasarettet, Karolinska Institutet foundation no. 176.

PII: S0049-3848(07)00123-5

doi:10.1016/j.thromres.2007.03.021

Thrombosis Research
Volume 121, Issue 2 , Pages 175-181, 2007